Oragenics, Inc. Announces Early Top-Line Results of Phase 2 Clinical Trial of AG013 for Oral Mucositis in Chemoradiation Treatment of Head and Neck Cancer
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against... Read More
Oragenics Working on Treatment for Oral Mucositis With Promising AG013 Product
Alan Joslyn, CEO of UF startup and UF Innovate | Sid Martin Biotech alum Oragenics, Inc., a Tampa-based company leader in the... Read More
Oragenics, Inc. Announces Completion of Enrollment of Its Phase 2 Clinical Trial for AG013 in Oral Mucositis
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against... Read More
Oragenics, Inc. Publishes Peer-Reviewed Study in Journal of Peptide Science
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of new antibiotics against... Read More
Oragenics Making ‘Great Progress’ Enrolling Patients in Oral Mucositis Clinical Trial
UF startup and UF Innovate | Sid Martin Biotech graduate company Oragenics, Inc., a leader in the development of novel antibiotics against... Read More
Oragenics Presents Interim Data on the AG013 Phase 2 Clinical Trial at the European Society for Medical Oncology Congress 2019
UF startup Oragenics, Inc., a leader in the development of novel antibiotics against infectious diseases and effective treatments for oral mucositis, announced... Read More
Oragenics, Inc. to Present Overview of Lantibiotics Pipeline at the Annual Military Health System Research Symposium
UF startup Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective treatments for oral mucositis, announced... Read More
Recent Peer-Reviewed Publication on Oragenics, Inc.’s Lantibiotic Antimicrobial Compound Identifies Alternative Mechanism of Action
UF Innovate | Sid Martin Biotech client Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and effective... Read More
BSI Team Joins Forces With Oragenics in Search for New Antibiotics
A biophysics team led by Florida International University researchers Prem Chapagain and Bernard Gerstman has joined forces with UF Innovate | Sid... Read More
Oragenics, Inc. Announces Enrollment of 60th Patient in Clinical Trial
UF Innovate | Sid Martin Biotech resident client Oragenics, Inc., a leader in the development of new antibiotics against infectious diseases and... Read More
